SHR-1701 is named as an intervention in 11 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (2). The most-studied condition is Gastroesophageal Junction Adenocarcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
NCT07175220 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
NCT07311408 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | Recruiting | Jingdong Zhang | China |
|
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
NCT07384234 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | Recruiting | Ruijin Hospital | China |
|
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
NCT07464756 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma
|
Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | China |
|
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
NCT07689851 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | China |
|
SHR-1701 Combined with SHR2554 and BP102 for MCRC
NCT06679673 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic
|
Phase 2 | Not yet open | Fudan University | China |
|
SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
NCT07524374 · ClinicalTrials.gov ↗ · ESCC
|
Phase 2 | Not yet open | Zhigang Li | China |
|
A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction
NCT07607210 · ClinicalTrials.gov ↗ · Siewert Type II Adenocarcinoma of the Esophagogastric Junction
|
Phase 2 | Not yet open | Hebei Medical University Fourth Hospital | China |
|
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
NCT07802184 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
|
Phase 1/2 | Not yet open | West China Hospital | China |
|
Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
NCT07806110 · ClinicalTrials.gov ↗ · Pancreas Ductal Adenocarcinoma
|
Phase 2 | Active, closed | The First Hospital of Jilin University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gastroesophageal Junction Adenocarcinoma | 3 |
| Gastric Cancer (GC) | 2 |
| Pancreas Ductal Adenocarcinoma | 1 |
| Advanced Gastric Cancer | 1 |
| Metastatic Gastric Cancer | 1 |
| Colorectal Cancer Metastatic | 1 |
| Locally Advanced Pancreatic Cancer | 1 |
| Metastatic Pancreatic Cancer | 1 |
| Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 1 |
| Siewert Type II Adenocarcinoma of the Esophagogastric Junction | 1 |
| Gastric Adenocarcinoma | 1 |
| ESCC | 1 |
| Locally Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 2 |
| The First Hospital of Jilin University | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Jingdong Zhang | 1 |
| Fudan University | 1 |
| West China Hospital | 1 |
| Ruijin Hospital | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Zhigang Li | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 11 | 6 |
A trial with sites in more than one country appears in each of those registers.
11 current trials in our China register name SHR-1701 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 11 trials are recruiting: 6 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jiangsu HengRui Medicine Co., Ltd (2), The First Hospital of Jilin University (1), Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) and Jingdong Zhang (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SHR-1701 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SHR-1701 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SHR-1701 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.